Search Results

The deal adds Kymab’s lead asset KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.

Kymab, a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody-based therapeutics, today announced that abstracts describing two lead hematology programs, KY1049 and KY1066, will be presented at the American Society of Hematology 61st Annual Meeting and Exposition, being held December 7-10, 2019 in Orlando, Florida.

MoonLake Immunotherapeutics AG today announced the appointment of Mr. Sturge as Chairman.

Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, todayannounced a poster presentation detailing updates on the ongoing clinical trial of the company’s anti-ICOS program KY1044 at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

Phase 1/2, open-label, multicenter study ongoing to evaluate KY1044 as a single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with advanced malignancies Cambr

ORI Capital announced Thursday that it has raised more than a quarter of a billion dollars for its second life sciences fund, which will invest in early-stage biotech companies using the firm’s proprietary AI-driven platform.